Yksilöllinen kemoterapia (annoksen säätely tai viive)

Corsetti MT, Salvi F, Perticone S, Baraldi A, De Paoli L, Gatto S, Pietrasanta D, Pini M, Primon V, Zallio F, Tonso A, Alvaro MG, Ciravegna G, Levis A.

Lähde‎: Leuk Res 2011;35(8):991-7.

Arkistoitu‎: PubMed 21474179

DOI‎: 10.1016/j.leukres.2011.02.021

https://www.ncbi.nlm.nih.gov/pubmed/21474179 (avaa uuden ikkunan)

Arsenic trioxide during consolidation for patients with previously untreated low/intermediate risk acute promyelocytic leukaemia may eliminate the need for maintenance therapy. (avaa uuden ikkunan)

Coutre SE, Othus M, Powell B, Willman CL, Stock W, Paietta E, Levitan D, Wetzler M, Attar EC, Altman JK, Gore SD, Maher T, Kopecky KJ, Tallman MS, Larson RA, Appelbaum FR.

Lähde‎: Br J Haematol 2014;165(4):497-503.

Arkistoitu‎: PubMed 24528179

DOI‎: 10.1111/bjh.12775

https://www.ncbi.nlm.nih.gov/pubmed/24528179 (avaa uuden ikkunan)

Low-dose cytosine arabinoside as an alternative treatment for acute leukemia in Jehovah's Witnesses. (avaa uuden ikkunan)

Dainer PM, Knupp CL, Sartiano GP.

Lähde‎: Am J Hematol 1992;40(2):156-7.

Arkistoitu‎: PubMed 1585917

https://www.ncbi.nlm.nih.gov/pubmed/1585917 (avaa uuden ikkunan)

Dose-dense rituximab-CHOP compared with standard rituximab-CHOP in elderly patients with diffuse large B-cell lymphoma (the LNH03-6B study): a randomised phase 3 trial. (avaa uuden ikkunan)

Delarue R, Tilly H, Mounier N, Petrella T, Salles G, Thieblemont C, Bologna S, Ghesquières H, Hacini M, Fruchart C, Ysebaert L, Fermé C, Casasnovas O, Van Hoof A, Thyss A, Delmer A, Fitoussi O, Molina TJ, Haioun C, Bosly A.

Lähde‎: Lancet Oncol 2013;14(6):525-33.

Arkistoitu‎: PubMed 23578722

DOI‎: 10.1016/S1470-2045(13)70122-0

https://www.ncbi.nlm.nih.gov/pubmed/23578722 (avaa uuden ikkunan)

Azacitidine and venetoclax in previously untreated acute myeloid leukemia. (avaa uuden ikkunan)

DiNardo CD, Jonas BA, Pullarkat V, Thirman MJ, Garcia JS, Wei AH, Konopleva M, Döhner H, Letai A, Fenaux P, Koller E, Havelange V, Leber B, Esteve J, Wang J, Pejsa V, Hájek R, Porkka K, Illés Á, Lavie D, Lemoli RM, Yamamoto K, Yoon SS, Jang JH, Yeh SP, Turgut M, Hong WJ, Zhou Y, Potluri J, Pratz KW

Lähde‎: N Engl J Med 2020;383(7):617-29.

Arkistoitu‎: PubMed 32786187

DOI‎: 10.1056/NEJMoa2012971

https://www.ncbi.nlm.nih.gov/pubmed/32786187 (avaa uuden ikkunan)

Treatment of acute leukaemia in adult Jehovah's Witnesses. (avaa uuden ikkunan)

El Chaer F, Ballen KK

Lähde‎: Br J Haematol 2020;190(5):696-707.

Arkistoitu‎: PubMed 31693175

DOI‎: 10.1111/bjh.16284

https://www.ncbi.nlm.nih.gov/pubmed/31693175 (avaa uuden ikkunan)

Minimally-myelosuppressive asparaginase-containing induction regimen for treatment of a Jehovah's Witness with mutant IDH1/NPM1/NRAS acute myeloid leukemia. (avaa uuden ikkunan)

Emadi A, Bade NA, Stevenson B, Singh Z.

Lähde‎: Pharmaceuticals (Basel) 2016;9(1):E12.

Arkistoitu‎: PubMed 27064021

DOI‎: 10.3390/ph9010012

https://www.ncbi.nlm.nih.gov/pubmed/27064021 (avaa uuden ikkunan)

Bevacizumab alone and in combination with irinotecan in recurrent glioblastoma. (avaa uuden ikkunan)

Friedman HS, Prados MD, Wen PY, Mikkelsen T, Schiff D, Abrey LE, Yung WK, Paleologos N, Nicholas MK, Jensen R, Vredenburgh J, Huang J, Zheng M, Cloughesy T.

Lähde‎: J Clin Oncol 2009;27(28):4733-40.

Arkistoitu‎: PubMed 19720927

DOI‎: 10.1200/JCO.2008.19.8721

https://www.ncbi.nlm.nih.gov/pubmed/19720927 (avaa uuden ikkunan)

Successful treatment of a Jehovah's Witness with acute promyelocytic leukemia. (avaa uuden ikkunan)

Fujita H, Maruta A, Koharazawa H, Hattori M, Tomit N, Kodama F, Mohri H, Okubo T.

Lähde‎: Int J Hematol 1997;65(4):415-6.

Arkistoitu‎: PubMed 9195782

https://www.ncbi.nlm.nih.gov/pubmed/9195782 (avaa uuden ikkunan)

Induction with azacytidine followed by allogeneic hematopoietic stem cell transplantation in a Jehovah's Witness with acute monocytic leukemia. (avaa uuden ikkunan)

Garelius H, Grund S, Stockelberg D.

Lähde‎: Clin Case Rep 2015;3(5):287-90.

Arkistoitu‎: PubMed 25984306

https://www.ncbi.nlm.nih.gov/pubmed/25984306 (avaa uuden ikkunan)

Immediate or delayed therapy with 2-CdA for hairy cell leukemia in Jehova's Witness? (avaa uuden ikkunan)

Juliusson G.

Lähde‎: Am J Hematol 1996;53(1):49.

Arkistoitu‎: PubMed 8813099

DOI‎: 10.1002/(SICI)1096-8652(199609)53:1<49::AID-AJH12>3.0.CO;2-Z

https://www.ncbi.nlm.nih.gov/pubmed/8813099 (avaa uuden ikkunan)

Tailored therapy of adult acute leukaemia in Jehovah's Witnesses: unjustified reluctance to treat. (avaa uuden ikkunan)

Laszlo D, Agazzi A, Goldhirsch A, Cinieri S, Bertolini F, Rabascio C, Pruneri G, Calabrese L, Cocquio A, Martinelli G.

Lähde‎: Eur J Haematol 2004;72(4):264-7.

Arkistoitu‎: PubMed 15089764

DOI‎: 10.1111/j.0902-4441.2003.00211.x

https://www.ncbi.nlm.nih.gov/pubmed/15089764 (avaa uuden ikkunan)

Successful treatment of acute promyelocytic leukemia in a pregnant Jehovah's Witness with all-trans retinoic acid, rhG-CSF, and erythropoietin. (avaa uuden ikkunan)

Lin CP, Huang MJ, Liu HJ, Chang IY, Tsai CH.

Lähde‎: Am J Hematol 1996;51(3):251-2.

Arkistoitu‎: PubMed 8619417

DOI‎: 10.1002/(SICI)1096-8652(199603)51:3<251::AID-AJH20>3.0.CO;2-I

https://www.ncbi.nlm.nih.gov/pubmed/8619417 (avaa uuden ikkunan)

Long-term efficacy of low-dose all-trans retinoic acid plus minimal chemotherapy induction followed by the addition of intravenous arsenic trioxide post-remission therapy in newly diagnosed acute promyelocytic leukaemia. (avaa uuden ikkunan)

Lou Y, Qian W, Meng H, Mai W, Tong H, Tong Y, Huang J, Jin J.

Lähde‎: Hematol Oncol 2014;32(1):40-6.

Arkistoitu‎: PubMed 23963734

DOI‎: 10.1002/hon.2076

https://www.ncbi.nlm.nih.gov/pubmed/23963734 (avaa uuden ikkunan)

Cytarabine dose for acute myeloid leukemia. (avaa uuden ikkunan)

Löwenberg B, Pabst T, Vellenga E, van Putten W, Schouten HC, Graux C, Ferrant A, Sonneveld P, Biemond BJ, Gratwohl A, de Greef GE, Verdonck LF, Schaafsma MR, Gregor M, Theobald M, Schanz U, Maertens J, Ossenkoppele GJ; Dutch-Belgian Cooperative Trial Group for Hemato-Oncology (HOVON) and Swiss Group for Clinical Cancer Research (SAKK) Collaborative Group.

Lähde‎: N Engl J Med 2011;364(11):1027-36.

Arkistoitu‎: PubMed 21410371

DOI‎: 10.1056/NEJMoa1010222

https://www.ncbi.nlm.nih.gov/pubmed/21410371 (avaa uuden ikkunan)

Myeloablative therapy and bone marrow transplantation in Jehovah's Witnesses with malignancies: single center experience. (avaa uuden ikkunan)

Mazza P, Prudenzano A, Amurri B, Palazzo G, Pisapia G, Stani L, Pricolo G.

Lähde‎: Bone Marrow Transplant 2003;32(4):433-6.

Arkistoitu‎: PubMed 12900781

DOI‎: 10.1038/sj.bmt.1704179

https://www.ncbi.nlm.nih.gov/pubmed/12900781 (avaa uuden ikkunan)

Ivosidenib and azacitidine in IDH1-mutated acute myeloid leukemia. (avaa uuden ikkunan)

Montesinos P, Recher C, Vives S, Zarzycka E, Wang J, Bertani G, Heuser M, Calado RT, Schuh AC, Yeh SP, Daigle SR, Hui J, Pandya SS, Gianolio DA, de Botton S, Döhner H

Lähde‎: N Engl J Med. 2022;386(16):1519-31.

Arkistoitu‎: PubMed 35443108

DOI‎: 10.1056/NEJMoa2117344

https://pubmed.ncbi.nlm.nih.gov/35443108/ (avaa uuden ikkunan)

Effect of chemotherapy delays and dose reductions on progression free and overall survival in the treatment of epithelial ovarian cancer. (avaa uuden ikkunan)

Nagel CI, Backes FJ, Hade EM, Cohn DE, Eisenhauer EL, O'Malley DM, Fowler JM, Copeland LJ, Salani R.

Lähde‎: Gynecol Oncol 2012;124(2):221-4.

Arkistoitu‎: PubMed 22055764

DOI‎: 10.1016/j.ygyno.2011.10.003

https://www.ncbi.nlm.nih.gov/pubmed/22055764 (avaa uuden ikkunan)

The treatment of acute lymphoblastic leukemia in Jehovah's Witnesses and patients who cannot accept blood products. (avaa uuden ikkunan)

Nguyen N, Madarang E, Alencar A, Watts J, Bradley T

Lähde‎: Leuk Res Rep. 2022 25;18:100355.

Arkistoitu‎: PubMed 36338830

DOI‎: 10.1016/j.lrr.2022.100355

https://pubmed.ncbi.nlm.nih.gov/36338830/ (avaa uuden ikkunan)

Developing a blood conservation care plan for Jehovah's Witness patients with malignant disease. (avaa uuden ikkunan)

Norfolk DR, Wade P, Carter R.

Lähde‎: Presented at the British Society for Haematology 47th Annual Scientific Meeting, Bournemouth [UK] April 2007.

https://www.transfusionguidelines.org/document-library/documents/developing-a-blood-conservation-care-plan-for-jehovah-s-witness-patients-with-malignant-disease/download-file/bbt-JW-Care-Plan-Malignant-Disease-2012.pdf (avaa uuden ikkunan)

High-dose chemotherapy without transfusion for Philadelphia chromosome negative B-cell acute lymphoblastic leukemia in two Jehovah's Witnesses patients: a feasible option in the age of hematopoietic growth factors. (avaa uuden ikkunan)

Perol L, Grignano E, Contejean A, Gastaud L, Legoff M, Franchi P, Deau-Fischer B, Willems L, Bouscary D, Tamburini J

Lähde‎: Leuk Lymphoma. 2019;60(9):2324-7.

Arkistoitu‎: PubMed 30773115

DOI‎: 10.1080/10428194.2019.1577414

https://www.ncbi.nlm.nih.gov/pubmed/30773115 (avaa uuden ikkunan)

Hematopoietic growth factors: personalization of risks and benefits. (avaa uuden ikkunan)

Puhalla S, Bhattacharya S, Davidson NE.

Lähde‎: Mol Oncol 2012;6(2):237-41.

Arkistoitu‎: PubMed 22497867

DOI‎: 10.1016/j.molonc.2012.03.001

https://www.ncbi.nlm.nih.gov/pubmed/22497867 (avaa uuden ikkunan)

Bloodless chimeric antigen receptor (CAR) T-cell therapy in Jehovah's Witnesses. (avaa uuden ikkunan)

Riedell PA, Wu M, Collins JM, Gideon JM, Jakubowiak AJ, Kline JP, Kosuri S, Liu H, Smith SM, Bishop MR

Lähde‎: Leuk Lymphoma 2021;62(6):1497-501.

Arkistoitu‎: PubMed 33535838

DOI‎: 10.1080/10428194.2021.1876868

https://www.ncbi.nlm.nih.gov/pubmed/33535838 (avaa uuden ikkunan)

Ivosidenib induces deep durable remissions in patients with newly diagnosed IDH1-mutant acute myeloid leukemia. (avaa uuden ikkunan)

Roboz GJ, DiNardo CD, Stein EM, de Botton S, Mims AS, Prince GT, Altman JK, Arellano ML, Donnellan W, Erba HP, Mannis GN, Pollyea DA, Stein AS, Uy GL, Watts JM, Fathi AT, Kantarjian HM, Tallman MS, Choe S, Dai D, Fan B, Wang H, Zhang V, Yen KE, Kapsalis SM, Hickman D, Liu H, Agresta SV, Wu B, Attar EC, Stone RM

Lähde‎: Blood 2020;135(7):463-71.

Arkistoitu‎: PubMed 31841594

DOI‎: 10.1182/blood.2019002140

https://www.ncbi.nlm.nih.gov/pubmed/31841594 (avaa uuden ikkunan)

Bloodless (transfusion-free) hematopoietic stem cell transplants: the Mexican experience. (avaa uuden ikkunan)

Ruiz-Argüelles GJ, Morales-Toquero A, López-Martínez B, Tarín-Arzaga LD, Manzano C.

Lähde‎: Bone Marrow Transplant 2005;36(8):715-20.

Arkistoitu‎: PubMed 16113672

DOI‎: 10.1038/sj.bmt.1705126

https://www.ncbi.nlm.nih.gov/pubmed/16113672 (avaa uuden ikkunan)

A Mexican way to cope with stem cell grafting. (avaa uuden ikkunan)

Ruiz-Delgado GJ, Ruiz-Argüelles GJ.

Lähde‎: Hematology 2012;17 Suppl 1:S195-7.

Arkistoitu‎: PubMed 22507819

DOI‎: 10.1179/102453312X13336169157130

https://www.ncbi.nlm.nih.gov/pubmed/22507819 (avaa uuden ikkunan)

Management of acute promyelocytic leukemia: recommendations from an expert panel on behalf of the European LeukemiaNet. (avaa uuden ikkunan)

Sanz MA, Grimwade D, Tallman MS, Lowenberg B, Fenaux P, Estey EH, Naoe T, Lengfelder E, Büchner T, Döhner H, Burnett AK, Lo-Coco F.

Lähde‎: Blood 2009;113(9):1875-91.

Arkistoitu‎: PubMed 18812465

DOI‎: 10.1182/blood-2008-04-150250

https://www.ncbi.nlm.nih.gov/pubmed/18812465 (avaa uuden ikkunan)

SCT in Jehovah's Witnesses: the bloodless transplant. (avaa uuden ikkunan)

Sloan JM, Ballen K.

Lähde‎: Bone Marrow Transplant 2008;41(10):837-44.

Arkistoitu‎: PubMed 18246110

DOI‎: 10.1038/bmt.2008.5

https://www.ncbi.nlm.nih.gov/pubmed/18246110 (avaa uuden ikkunan)

Treatment of acute myelogenous leukemia with outpatient azacitidine. (avaa uuden ikkunan)

Sudan N, Rossetti JM, Shadduck RK, Latsko J, Lech JA, Kaplan RB, Kennedy M, Gryn JF, Faroun Y, Lister J.

Lähde‎: Cancer 2006;107(8):1839-43.

Arkistoitu‎: PubMed 16967444

DOI‎: 10.1002/cncr.22204

https://www.ncbi.nlm.nih.gov/pubmed/16967444 (avaa uuden ikkunan)

Isolated limb perfusion for an irresectable melanoma recurrence in a Jehovah's Witness. (avaa uuden ikkunan)

van Akkooi AC, Golab-Schwarz HD, Eggermont AM, van Geel AN.

Lähde‎: Eur J Cardiothorac Surg 2006;30(2):408-10.

Arkistoitu‎: PubMed 16829108

DOI‎: 10.1016/j.ejcts.2006.04.020

https://www.ncbi.nlm.nih.gov/pubmed/16829108 (avaa uuden ikkunan)

Management of cytopenias in patients with myelofibrosis treated with ruxolitinib and effect of dose modifications on efficacy outcomes. (avaa uuden ikkunan)

Verstovsek S, Gotlib J, Gupta V, Atallah E, Mascarenhas J, Quintas-Cardama A, Sun W, Sarlis NJ, Sandor V, Levy RS, Kantarjian HM, Mesa RA.

Lähde‎: Onco Targets Ther 2013;7:13-21.

Arkistoitu‎: PubMed 24368888

DOI‎: 10.2147/OTT.S53348

https://www.ncbi.nlm.nih.gov/pubmed/24368888 (avaa uuden ikkunan)

Bevacizumab plus irinotecan in recurrent glioblastoma multiforme. (avaa uuden ikkunan)

Vredenburgh JJ, Desjardins A, Herndon JE 2nd, Marcello J, Reardon DA, Quinn JA, Rich JN, Sathornsumetee S, Gururangan S, Sampson J, Wagner M, Bailey L, Bigner DD, Friedman AH, Friedman HS.

Lähde‎: J Clin Oncol 2007;25(30):4722-9.

Arkistoitu‎: PubMed 17947719

DOI‎: 10.1200/JCO.2007.12.2440

https://www.ncbi.nlm.nih.gov/pubmed/17947719 (avaa uuden ikkunan)

Venetoclax plus LDAC for newly diagnosed AML ineligible for intensive chemotherapy: a phase 3 randomized placebo-controlled trial. (avaa uuden ikkunan)

Wei AH, Montesinos P, Ivanov V, DiNardo CD, Novak J, Laribi K, Kim I, Stevens DA, Fiedler W, Pagoni M, Samoilova O, Hu Y, Anagnostopoulos A, Bergeron J, Hou JZ, Murthy V, Yamauchi T, McDonald A, Chyla B, Gopalakrishnan S, Jiang Q, Mendes W, Hayslip J, Panayiotidis P

Lähde‎: Blood 2020;135(24):2137-45.

Arkistoitu‎: PubMed 32219442

DOI‎: 10.1182/blood.2020004856

https://www.ncbi.nlm.nih.gov/pubmed/32219442 (avaa uuden ikkunan)